Onconic Therapeutics Inc. (KOSDAQ:476060)

Onconic Therapeutics Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	16,754	-8,093	1,682	-14,432	-15,149
Depreciation & Amortization	452.67	452.67	460.13	199.66	181.88
Other Amortization	-	-	-	1.18	1.08
Loss (Gain) From Sale of Assets	-	-	0.7	-	-
Stock-Based Compensation	1,026	1,026	578.03	472.48	163.17
Other Operating Activities	-4,928	4,427	-774.88	-277.64	6,829
Change in Accounts Receivable	-7,222	-7,222	104.5	-99	-5.5
Change in Accounts Payable	708.67	708.67	-	-	-
Change in Income Taxes	463.39	463.39	-	-	-
Change in Other Net Operating Assets	39.47	396.57	2,089	-825.75	-879.32
Operating Cash Flow	7,293	-7,841	4,140	-14,961	-8,859
Capital Expenditures	-211.35	-141.28	-1,157	-2,575	-2.67
Sale of Property, Plant & Equipment	-	-	38	-	-
Sale (Purchase) of Intangibles	-	-	-	-	-5.88
Other Investing Activities	4.97	70.42	108.76	135.75	-
Investing Cash Flow	-7,175	-70.85	-1,011	-2,439	-8.55
Long-Term Debt Repaid	-	-179.92	-153.85	-142.06	-142.06
Net Debt Issued (Repaid)	-194.35	-179.92	-153.85	-142.06	-142.06
Issuance of Common Stock	20,994	19,762	-	-	7,498
Other Financing Activities	-	-	114	-	-
Financing Cash Flow	20,800	19,582	-39.85	25,858	27,356
Foreign Exchange Rate Adjustments	1,216	1,229	-196.39	-	-
Miscellaneous Cash Flow Adjustments	-	-	-108.76	-	-
Net Cash Flow	22,134	12,899	2,784	8,458	18,488
Free Cash Flow	7,082	-7,982	2,983	-17,536	-8,861
Free Cash Flow Margin	15.18%	-53.79%	14.16%	-18458.96%	-14769.11%
Free Cash Flow Per Share	-	-244.07	1290.10	-758.49	-386.90
Cash Income Tax Paid	1,379	912.06	2,170	2.18	2.71
Levered Free Cash Flow	548.32	-50,062	16,304	13,630	-
Unlevered Free Cash Flow	557.1	-49,646	17,413	14,304	-
Change in Working Capital	-6,010	-5,653	2,193	-924.75	-884.82

Source: S&P Global Market Intelligence. Standard template. Financial Sources.